Ossio, a Woburn, MA-based orthopedic fixation company, closed a $22m in equity financing.
The round, which brought total funding raised to date to $35m, was led by OCV Partners, with participation from existing investors Ortho Vision LLC and Secocha Ventures. In conjunction with funding, Zohar Loshitzer, Principal at OCV, will be joining the Ossio’s Board of Directors.
The company will use these funds to accelerate strategic growth initiatives, including talent acquisition, commercialization, new product development and operational expansion.
Led by Brian Verrier, CEO, Ossio is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors. Founded in 2014, the company has developed the OSSIOfiberTM Intelligent Bone Regeneration Technology, and recently received 510(k) market clearance from the U.S. Food & Drug Administration for its OSSIOfiberTM Bone Pin Family, an implant system that uses a proprietary bio-integrative material to provide stability and maintain the alignment of bone fractures, osteotomies, arthrodesis and bone grafts during the healing process, leaving no permanent hardware behind. While OSSIOfiberTM will have broad application across the spectrum of orthopedic fixation, its first commercial use is focused in the foot and ankle segment for the treatment of forefoot conditions where hardware removal surgeries are prevalent.
Ossio’s development headquarters is located in Caesarea, Israel,